177A logo

Kohjin Bio TSE:177A Stock Report

Last Price

JP¥1.75k

Market Cap

JP¥8.9b

7D

-6.1%

1Y

n/a

Updated

21 Nov, 2024

Data

Company Financials +

177A Stock Overview

Manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. More details

177A fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance1/6
Financial Health5/6
Dividends0/6

Kohjin Bio Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kohjin Bio
Historical stock prices
Current Share PriceJP¥1,745.00
52 Week HighJP¥3,065.00
52 Week LowJP¥1,281.00
Beta0
11 Month Change-3.06%
3 Month Change-2.84%
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-26.37%

Recent News & Updates

Recent updates

Shareholder Returns

177AJP BiotechsJP Market
7D-6.1%-5.5%-0.4%
1Yn/a15.4%11.4%

Return vs Industry: Insufficient data to determine how 177A performed against the JP Biotechs industry.

Return vs Market: Insufficient data to determine how 177A performed against the JP Market.

Price Volatility

Is 177A's price volatile compared to industry and market?
177A volatility
177A Average Weekly Movement4.8%
Biotechs Industry Average Movement8.3%
Market Average Movement3.8%
10% most volatile stocks in JP Market7.6%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 177A has not had significant price volatility in the past 3 months compared to the JP market.

Volatility Over Time: 177A's weekly volatility has decreased from 11% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1981159Takahito Nakamurawww.kohjin-bio.jp

Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags and other materials; cryopreservation agent of cells; medium supplements; normal human cells; normal human cell mediums; ES cell mediums; in-vitro fertilization and early embryo culture kits; and other culture and related products, such as supplements, cell separation solutions, physiological salt solutions, and research reagents. The company also offers clinical microbiology culture mediums for gram positive cocci, gram negative bacteria, and susceptibility testing; general differential, anaerobic growth, and fungal mediums; tube mediums for confirmation and expansion; microbiology culture mediums for food, such as mediums for sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, and vibrio parahaemolyticus; culture mediums for determining total viable cell count; and campylobacter and fungal mediums.

Kohjin Bio Co., Ltd. Fundamentals Summary

How do Kohjin Bio's earnings and revenue compare to its market cap?
177A fundamental statistics
Market capJP¥8.92b
Earnings (TTM)JP¥384.00m
Revenue (TTM)JP¥4.77b

23.2x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
177A income statement (TTM)
RevenueJP¥4.77b
Cost of RevenueJP¥2.89b
Gross ProfitJP¥1.88b
Other ExpensesJP¥1.50b
EarningsJP¥384.00m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)75.12
Gross Margin39.43%
Net Profit Margin8.05%
Debt/Equity Ratio65.1%

How did 177A perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

15%

Payout Ratio